Supplementary Materials, Figures 1 - 3, Tables 1 - 4, 6 - 8 from the 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease

Yi-Ping Fu,Indu Kohaar,Lee E. Moore,Petra Lenz,Jonine D. Figueroa,Wei Tang,Patricia Porter-Gill,Nilanjan Chatterjee,Alexandra Scott-Johnson,Montserrat Garcia-Closas,Brian Muchmore,Dalsu Baris,Ashley Paquin,Kris Ylaya,Molly Schwenn,Andrea B. Apolo,Margaret R. Karagas,McAnthony Tarway,Alison Johnson,Adam Mumy,Alan Schned,Liliana Guedez,Michael A. Jones,Masatoshi Kida,GM Monawar Hosain,Nuria Malats,Manolis Kogevinas,Adonina Tardon,Consol Serra,Alfredo Carrato,Reina Garcia-Closas,Josep Lloreta,Xifeng Wu,Mark Purdue,Gerald L. Andriole,Robert L. Grubb,Amanda Black,Maria T. Landi,Neil E. Caporaso,Paolo Vineis,Afshan Siddiq,H. Bas Bueno-de-Mesquita,Dimitrios Trichopoulos,Börje Ljungberg,Gianluca Severi,Elisabete Weiderpass,Vittorio Krogh,Miren Dorronsoro,Ruth C. Travis,Anne Tjønneland,Paul Brennan,Jenny Chang-Claude,Elio Riboli,Jennifer Prescott,Constance Chen,Immaculata De Vivo,Edward Govannucci,David Hunter,Peter Kraft,Sara Lindstrom,Susan M. Gapstur,Eric J. Jacobs,W. Ryan Diver,Demetrius Albanes,Stephanie J. Weinstein,Jarmo Virtamo,Charles Kooperberg,Chancellor Hohensee,Rebecca J. Rodabough,Victoria K. Cortessis,David V. Conti,Manuela Gago-Dominguez,Mariana C. Stern,Malcolm C. Pike,David Van Den Berg,Jian-Min Yuan,Christopher A. Haiman,Olivier Cussenot,Geraldine Cancel-Tassin,Morgan Roupret,Eva Comperat,Stefano Porru,Angela Carta,Sofia Pavanello,Cecilia Arici,Giuseppe Mastrangelo,H. Barton Grossman,Zhaoming Wang,Xiang Deng,Charles C. Chung,Amy Hutchinson,Laurie Burdette,William Wheeler,Joseph Fraumeni,Stephen J. Chanock,Stephen M. Hewitt,Debra T. Silverman,Nathaniel Rothman,Ludmila Prokunina-Olsson

DOI: https://doi.org/10.1158/0008-5472.22403567.v1

2023-01-01

Abstract:Supplementary Figure 1: Electrophoretic mobility shift assays (EMSA) for CCNE1 SNPs rs8102137 and rs7257330. Supplementary Figure 2: Alignment of cyclin E protein isoforms - WT1, WT2 and ES and ET. Supplementary Figure 3: Functional analysis of cyclin E isoforms.Supplementary Table 1: Description of sub-studies included in NCI-GWAS1 and GWAS2 of bladder cancer. Supplementary Table 2: Characteristics of bladder tissue samples used for mRNA expression analysis. Supplementary Table 3: PCR primers, genotyping and gene expression assays, EMSA probes and antibodies. Supplementary Table 4: Bladder cancer stage and grade information for patients in the combined GWAS1+2 set. Supplementary Table 6: Association with bladder cancer risk with mutual adjustment for CCNE1 variants. Supplementary Table 7: Association with bladder cancer risk for CCNE1 variants previously associated with other cancers and for two non-synonymous coding variants. Supplementary Table 8: Association between cyclin E protein expression (IHC scores), bladder cancer patient characteristics and CCNE1 variants.